SAVE NEPALI PHARMACEUTICAL INDUSTRIES

Nepali pharmaceutical companies are the backbone of the country's health security and economic self-reliance, currently meeting approximately 45% to 50% of the nation’s total medicine demand. They provide essential, high-quality generic drugs—such as antibiotics, cardiac medications, and diabetes treatments—at significantly lower prices than imported alternatives, often being the only reason life-saving drugs those remain affordable for the general public. Beyond healthcare, the sector is a major industrial pillar that employs around 40,000 people and has attracted billions in private investment, reducing the country's dangerous over-reliance on imports from India and China. During global supply chain disruptions or border blockades, these local manufacturers act as a critical safety net, ensuring that pharmacies across the "nooks and corners" of Nepal do not run dry. The Risk of majority of Nepal's pharmaceutical industries closing down after LDC Graduation: When Nepal graduates from Least Developed Country (LDC) status in November 2026, the pharmaceutical sector faces an existential "patent cliff" due to the loss of TRIPS flexibilities. End of Patent Exemptions: As an LDC, Nepal is currently exempt from enforcing pharmaceutical patents. Local labs can legally produce generic versions of patented global drugs without paying expensive royalties. After 2026, they will be forced to pay these fees or stop production of newer, advanced molecules entirely. Skyrocketing Production Costs: Industry experts warn that the cost of producing essential medicines could double or triple. Since Nepali companies already struggle with high taxes on imported raw materials and stagnant government-fixed retail prices (some unchanged for 16 years), many will no longer be able to operate profitably. Loss of Export Potential: Graduation will lead to stricter "Rules of Origin" and higher tariffs, making it even harder for Nepali drugs to compete in international markets. The "Generic" Trap: While 90% of local production is off-patent generics, the remaining 10% (often the most profitable and advanced drugs for NCDs) will be hit first. Without a massive leap in Research & Development (R&D) and a new Intellectual Property (IP) law to protect local innovation, many smaller plants risk being out-competed by multinational giants, leading to potential closures and a rise in out-of-pocket healthcare costs for Nepalis. So, it's time Nepal Government needs to amend policies to mitigate this risk. We need collaboration among Ministry of Health & Population, Ministry of Industry & Ministry of Finance as soon as possible.